Acute Coronary Syndrome Market

Acute coronary syndrome is a group of diseases in which blood flow to the heart decreases or suddenly stops. When blood cannot flow to the heart muscle, the heart muscle can be damaged. Acute coronary syndrome includes unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction. This is caused due to fatty substances called plaque which can build up in the arteries that bring oxygen-rich blood to your heart. Plaque comprises cholesterol, fats, cells, and other substances. Plaque blocks the blood flow in two ways, one is it can cause the artery to become so narrow over time that it becomes blocked enough to cause symptoms and the other is the plaque tears suddenly and a blood clot forms around it, severely blocking or narrowing the artery. According to the National Center for Biotechnology Information (NCBI), studies of intravascular ultrasonography have shown that at least 80% of patients with acute coronary syndrome exhibit multiple plaque raptures distinct from the culprit lesions. The most common symptoms of acute coronary syndrome are chest pain, old people and women experience some other symptoms such as shortness of breath, fast and irregular heartbeat, sweating, and discomfort that occurs at rest and does not easily go away when you take medicine.

Unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction these high-risk manifestations of coronary atherosclerosis are important causes of medical care and hospitalization. High-risk patients with UA/NSTEMI are often treated with an early invasive strategy involving cardiac catheterization and prompt revascularization of viable myocardium at risk. Evidence-based guidelines provide recommendations for managing acute coronary syndrome and continue to evolve rapidly, driven by a multitude of large-scale randomized controlled trials.

Global Acute Coronary Syndrome Market – Competitive Landscape

Translational investigators and companies face a challenging economic environment when seeking funds to move preclinical stage research into human testing and beyond. Boston-based Broadview Ventures, created by the Laducq Family Trust, promotes the development of technology for diagnosing and treating cardiovascular disease and stroke through direct equity-based investments. In 2023 Bioworld Ventures portfolio company CorVista® has received its first FDA clearance for heart diseases. In 2023 Avertix, a maker of implantable heart attack warning systems announced it was undergoing a merger via a SPAC with Bios Acquisition Corp.

Some key players in the Global Acute Coronary Syndrome Market Include –

• Movinto
• Thermo Fisher Scientific Inc.
• Catalent Inc.
• Paraxel International Corporation
• Sharp
• PCI Pharma Services
• Almac Group
• Bionocal Ltd.

Global Acute Coronary Syndrome Market – Growth Drivers

Cardiovascular diseases represent the leading cause of death globally. According to Oxford University, sudden death causes most acute coronary syndrome, which represents the death of 1.8 million death per year. Biological drugs, stand to be a real game-changer in this sector. The principal trends in acute coronary syndrome are increasing utilization of percutaneous coronary and declining coronary artery bypass graft surgery. The Pharmacogenetics potential remains immense in terms of drug selection based on genetic profiles to control risk factors in patients with cardiovascular diseases. Changing patient behavior According to the National Center for Biotechnology Information (NCBI), 62% of smokers resumed smoking within a year after a myocardial infarction. There is continued demand for clinical and cost-effective solutions to coronary artery disease. In the largest product area, coronary stents, forecasted stent sales will grow at nearly double-digit rates result of continued innovations, increasing coronary artery disease prevalence, and robust emerging market uptake.

Global Acute Coronary Syndrome Market – Restraints

The substantial costs associated with acute coronary syndrome include treatment-related medical costs, as well as costs due to productivity. According to the National Center for Biotechnology Information (NCBI), the total one-year treatment cost is estimated to be USD 22,528 to USD 32,345, with the majority of these costs due to hospitalization. Barriers include the complexity of the interventions, relatively low government support, complexity of interventions, and a lack of recognition of chest pain in patients with acute coronary syndrome. In some regions, inadequate healthcare infrastructure may limit the ability to provide timely and effective acute coronary syndrome treatment.

Global Acute Coronary Syndrome Market – Opportunities

Utilizing the data analytics to gain insights into acute coronary syndrome trends, patient outcomes, and treatment effectiveness. Exploring the different ways to improve access to acute coronary syndrome care through insurance and financial support mechanisms. Increasing the use of technology for remote patient monitoring and telemedicine to provide timely care and reduce hospitalization. Collaborating with healthcare providers, research institutes, and pharmaceutical companies to accelerate research and development.

Global Acute Coronary Syndrome Market – Geographical Insight

Globally acute coronary syndrome market is segmented into the regions of North America, Latin America, Europe, Asia-Pacific, Middle East & Africa. North America is the largest acute coronary syndrome market due to the high prevalence of acute coronary syndrome, well-established healthcare infrastructure, different opportunities for innovative therapies, and digital health solutions. Asia-Pacific is anticipated to show the highest growth rate over the forecast period due to growing awareness about acute coronary artery syndrome and risk factors.

Global Acute Coronary Syndrome Market – Key Development

• Heartbeam Inc. has developed a state-of-the-art heart attack detection technology utilizing an innovative sensor in the form of a credit card-sized VECG recording device in 2023
• In 2023, Bristol Myers Squibb in collaboration with Johnson and Johnson announced prospective indications for milvexian, an investigational oral factor Xia inhibitor for acute coronary syndrome and ischemic heart disease as Fast Track Designation.
• On 11 September 2023, Atuliflaponis was under clinical development by AstraZeneca and is currently in phase II for acute coronary syndrome.